Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Identifieur interne : 000584 ( Hal/Checkpoint ); précédent : 000583; suivant : 000585Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Auteurs : Olivier Rascol [France]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2011-03.
English descriptors
- mix :
Abstract
Intermittent or pulsatile dopamine-receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long-term levodopa therapy of Parkinson's disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine-receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half-lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini-pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol-O-methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long-term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once-daily prolonged-release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once-daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.
Url:
DOI: 10.1111/j.1468-1331.2010.03326.x
Links toward previous steps (curation, corpus...)
Links to Exploration step
Hal:inserm-00564120Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-27445" status="VALID"><orgName>Imagerie cérébrale et handicaps neurologiques</orgName><desc><address><addrLine>Hopital de purpan place du docteur baylac service de neurologie - pavillon riser 31059 TOULOUSE CEDEX 9</addrLine><country key="FR"></country></address></desc><listRelation><relation active="#struct-217752" type="direct"></relation><relation name="U825" active="#struct-303623" type="direct"></relation></listRelation><tutelles><tutelle active="#struct-217752" type="direct"><org type="institution" xml:id="struct-217752" status="VALID"> <orgName>Université Paul Sabatier - Toulouse 3</orgName> <orgName type="acronym">UPS</orgName> <desc> <address> <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-tlse3.fr/</ref> </desc></org></tutelle><tutelle name="U825" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:inserm-00564120</idno><idno type="halId">inserm-00564120</idno><idno type="halUri">http://www.hal.inserm.fr/inserm-00564120</idno><idno type="url">http://www.hal.inserm.fr/inserm-00564120</idno><idno type="doi">10.1111/j.1468-1331.2010.03326.x</idno><date when="2011-03">2011-03</date><idno type="wicri:Area/Hal/Corpus">000336</idno><idno type="wicri:Area/Hal/Curation">000336</idno><idno type="wicri:Area/Hal/Checkpoint">000584</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000584</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-27445" status="VALID"><orgName>Imagerie cérébrale et handicaps neurologiques</orgName><desc><address><addrLine>Hopital de purpan place du docteur baylac service de neurologie - pavillon riser 31059 TOULOUSE CEDEX 9</addrLine><country key="FR"></country></address></desc><listRelation><relation active="#struct-217752" type="direct"></relation><relation name="U825" active="#struct-303623" type="direct"></relation></listRelation><tutelles><tutelle active="#struct-217752" type="direct"><org type="institution" xml:id="struct-217752" status="VALID"> <orgName>Université Paul Sabatier - Toulouse 3</orgName> <orgName type="acronym">UPS</orgName> <desc> <address> <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.univ-tlse3.fr/</ref> </desc></org></tutelle><tutelle name="U825" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></analytic><idno type="DOI">10.1111/j.1468-1331.2010.03326.x</idno><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><imprint><date type="datePub">2011-03</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Parkinson's disease</term><term>continuous dopaminergic stimulation</term><term>dopamine agonists</term><term>motor fluctuations</term><term>pramipexole extended-release</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intermittent or pulsatile dopamine-receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long-term levodopa therapy of Parkinson's disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine-receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half-lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini-pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol-O-methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long-term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once-daily prolonged-release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once-daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</div></front></TEI><hal api="V3"> <titleStmt> <title xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.</title> <author role="crp"> <persName> <forename type="first">Olivier</forename> <surname>Rascol</surname> </persName> <email type="md5">3c5c140301629a9918dd146008342264</email> <email type="domain">cict.fr</email> <idno type="halauthorid">577898</idno> <affiliation ref="#struct-27445"></affiliation> </author> <editor role="depositor"> <persName> <forename>Olivier</forename> <surname>Rascol</surname> </persName> <email type="md5">3c5c140301629a9918dd146008342264</email> <email type="domain">cict.fr</email> </editor> <funder>This article forms part of a supplement sponsored by Boehringer Ingelheim in collaboration with MedEd Global Solutions. OR has received consulting fees from Boehringer Ingelheim, Eisai, GlaxosmithKline, Novartis, Schering, Solvay, Teva Neuroscience, XenoPort, Oxford Bio- Medica, Movement Disorders Society, Lundbeck, Servier and UCB. OR has received scientific grants from Boehringer Ingelheim, Eisai, GlaxosmithKline, Novartis, Solvay, Teva Neuroscience and Lundbeck.</funder> </titleStmt> <editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2011-02-08 09:53:38</date> <date type="whenModified">2015-01-19 11:49:49</date> <date type="whenReleased">2011-02-08 10:46:52</date> <date type="whenProduced">2011-03</date> <date type="whenEndEmbargoed">9999-12-31</date> <ref type="file" target="http://www.hal.inserm.fr/inserm-00564120/document"> <date notBefore="9999-12-31"></date> </ref> <ref type="file" subtype="greenPublisher" n="1" target="http://www.hal.inserm.fr/inserm-00564120/file/Drug_delivery_PD-pramipexole-Pr_Rascol.pdf"> <date notBefore="9999-12-31"></date> </ref> </edition> <respStmt> <resp>contributor</resp> <name key="139737"> <persName> <forename>Olivier</forename> <surname>Rascol</surname> </persName> <email type="md5">3c5c140301629a9918dd146008342264</email> <email type="domain">cict.fr</email> </name> </respStmt> </editionStmt> <publicationStmt> <distributor>CCSD</distributor> <idno type="halId">inserm-00564120</idno> <idno type="halUri">http://www.hal.inserm.fr/inserm-00564120</idno> <idno type="halBibtex">rascol:inserm-00564120</idno> <idno type="halRefHtml">European Journal of Neurology, Wiley, 2011, 18 Suppl 1, pp.3-10. <10.1111/j.1468-1331.2010.03326.x></idno> <idno type="halRef">European Journal of Neurology, Wiley, 2011, 18 Suppl 1, pp.3-10. <10.1111/j.1468-1331.2010.03326.x></idno> </publicationStmt> <seriesStmt> <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno> <idno type="stamp" n="UNIV-TLSE3">Université Paul Sabatier - Toulouse III</idno> </seriesStmt> <notesStmt> <note type="audience" n="2">International</note> <note type="popular" n="0">No</note> <note type="peer" n="1">Yes</note> </notesStmt> <sourceDesc> <biblStruct> <analytic> <title xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.</title> <author role="crp"> <persName> <forename type="first">Olivier</forename> <surname>Rascol</surname> </persName> <email type="md5">3c5c140301629a9918dd146008342264</email> <email type="domain">cict.fr</email> <idno type="halauthorid">577898</idno> <affiliation ref="#struct-27445"></affiliation> </author> </analytic> <monogr> <idno type="halJournalId" status="VALID">13064</idno> <idno type="issn">1351-5101</idno> <idno type="eissn">1468-1331</idno> <title level="j">European Journal of Neurology</title> <imprint> <publisher>Wiley</publisher> <biblScope unit="volume">18 Suppl 1</biblScope> <biblScope unit="pp">3-10</biblScope> <date type="datePub">2011-03</date> </imprint> </monogr> <idno type="doi">10.1111/j.1468-1331.2010.03326.x</idno> <idno type="pubmed">21255197</idno> </biblStruct> </sourceDesc> <profileDesc> <langUsage> <language ident="en">English</language> </langUsage> <textClass> <keywords scheme="author"> <term xml:lang="en">continuous dopaminergic stimulation</term> <term xml:lang="en">dopamine agonists</term> <term xml:lang="en">motor fluctuations</term> <term xml:lang="en">Parkinson's disease</term> <term xml:lang="en">pramipexole extended-release</term> </keywords> <classCode scheme="halDomain" n="sdv.neu">Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]</classCode> <classCode scheme="halTypology" n="ART">Journal articles</classCode> </textClass> <abstract xml:lang="en">Intermittent or pulsatile dopamine-receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long-term levodopa therapy of Parkinson's disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine-receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half-lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini-pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol-O-methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long-term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once-daily prolonged-release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once-daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</abstract> </profileDesc> </hal></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000584 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000584 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Hal
|étape= Checkpoint
|type= RBID
|clé= Hal:inserm-00564120
|texte= Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
}}
| This area was generated with Dilib version V0.6.29. |  |